BACKGROUND: The concern over the use of electroencephalogram (EEG)diagnosis and biofeedback training as a viable option for children with attention deficit hyperactivity disorder(ADHD) has grown gradually.OBJECTIVE: To evaluate the diagnostic accuracy and therapeutic efficacy of A620 EEG system to ADHD children.DESIGN: Prospective observation and comparative study on ADHD children.SETTING: Psychological department of a municipal hospital.PARTICIPANTS: From October 2003 to May 2004, 113 outpatient children in Psychology Hyperactivity Department of the Central Hospital of Anshan City were selected. Inclusion criteria: 6 to 14-year-old outpatient children in Hyperactivity Department. Exclusion criteria: nervous system organic diseases, pervasive developmental disorder(PDD), mental retardation, epilepsy, psychotic disorder, acoustical and visual abnormalities,etc. Of all the ADHD children, 88 were male and 25 were female, with the mean age of(10 ± 3) years.METHODS: A620 EEG system was applied to examine the 113 participants. According to the Diagnostic Criteria for ADHD in Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition (DSM-Ⅳ), published by American Psychiatry Association, ADHD children were diagnosed and then the EEG diagnostic accuracy and specificity were calculated. The System was also used for biofeedback treatment on 27 ADHD children. Fluctuation of EEG θ/β value was measured both before and after treatment, and the change of hyperactivity index was investigated by Conners Parent Symptom Questionnaire as well.MAIN OUTCOME MEASURES: EEG θ/β value, Conners index of hyperactivity (CIH).RESULTS: The diagnostic sensitivity of EEG on ADHD was 83.58%, and the specificity of it was 82.61%; EEB θ/β value of post-treatment was 8.26 ±4.05, which decreased significantly compared with pre-treatment value (12.38 ± 7.96) ( t = 2. 39, P ＜ 0.05); CIH was also dramatically declined from(24. 73 ± 10. 96) (pre-treatment) to( 12.05 ± 8.63)(post-treatment) ( t= 4.72, P ＜ 0. 01 ).CONCLUSION: EEG can be used as an accessory method in ADHD diagnosis due to its high sensitivity and specificity. Abnormalities of brainwave and hyperactivities of ADHD patients can be greatly ameliorated by EEGbiofeedback treatment.

Objective: To explore the influential factors on tumor diameters in rectal cancer. Methods : Cross sectional study data were collected from patients undergoing radical resection of rectal cancer.Patients were grouped by median value of tumor diameter, and the clinical pathological characteristics were compared between the two groups.The associations between tumor diameter and continuous variables were analyzed using locally weighted scatterplot smoothing(LOWESS) method.The associating factors of tumor diameter were further analyzed using generalized additive model(GAM). Results : Patients with rectal cancer were divided into two groups with tumor diameter either<4 centimeters or ≥4 centimeters.Proportions of T,TNM stages differed significantly between different groups.Median carcinoembryonic antigen(CEA) in≥4 centimeters group were 4.90 ng/ml(inter-quartile range [IQR] 2.39,9.53 ng/ml),much higher than that in<4 centimeters group(2.93 ng/ml [IQR:1.78,4.90 ng/ml]),P<0.01.LOWESS analysis showed that there were non-linear relationships between tumor diameter and the following variables: age, the distance between tumor and anal verge, CEA,neutrophils, lymphocytes, platelets, neutrophil-to-lymphocyte ratio, and platelet-to-lymphocyte ratio.GAM showed that increased blood platelets(P<0.05) and later T stage(P<0.01) were significantly associated with increased tumor diameters, and increased CEA levels were also associated with larger tumors(P<0.01),but there were saturation effects. Conclusion Platelets, T stage and CEA are associated with tumor diameter in rectal cancer, indicating that the above factors should be considered when studying associated factors of tumor diameter in rectal cancer.

Objective:To evaluate the post-marketing safety and immunogenicity of a 23-valent pneumococcal polysaccharide vaccine (PPV23).Methods:From September 2020 to June 2021, a clinical trial of single-dose PPV23 was conducted in people ≥3 years old in Centers for Disease Control and Prevention of Guizhou, Hunan and Fujian provinces. Blood samples were collects from the subjects before and 30 d after vaccination. ELISA was used to quantitatively detect IgG antibodies against capsular polysaccharides of 23 Streptococcus pneumoniae serotypes in serum samples. The adverse events (AEs) were monitored within 7 d after vaccination. Results:A total of 409 subjects were enrolled and included in safety analysis. Except for one with antibody level inversion, the other 408 participants were included in immunogenicity analysis. The levels of antibodies against the 23 Streptococcus pneumoniae serotypes were all increased after vaccination by an average of 4.24 folds. The two-fold growth rates of the antibodies ranged from 51.72% to 96.81% with a total two-fold growth rate of 78.59%. The overall rate of AEs was 27.14% (111/409). Local AEs were mainly pain, induration, redness and swollen. No serious adverse events related to vaccination occurred. Conclusions:This study preliminarily demonstrated the good immunogenicity and safety of PPV23 vaccine.